DHA-clozapine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
DHA-clozapine
Docosahexaenoyl-clozapine.svg
Clinical data
Trade namesClozaprexin
Other namesDocosahexaenoyl clozapine
ATC code
  • none
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC40H49ClN4O
Molar mass637.31 g·mol−1
3D model (JSmol)
 ☒NcheckY (what is this?)  (verify)

DHA-clozapine (tentative trade name Clozaprexin)[1] is an atypical antipsychotic drug candidate that was created and originally tested by chemists at Protarga, a small pharmaceutical in Pennsylvania, and scientists at Harvard University.[2]

It is a prodrug of clozapine; the fatty acid docosahexaenoic acid (DHA) was added to clozapine in order to increase penetration of the blood–brain barrier.[3]

Protarga was purchased by Luitpold Pharmaceuticals in 2003 and development was discontinued in 2007.[1]


References[edit]

  1. ^ a b "DHA-clozapine". AdisInsight. Retrieved 17 March 2017.
  2. ^ Rosack, Jim (4 May 2001). "Targaceuticals Point Way To Developing Safer Drugs". Psychiatric News. doi:10.1176/pn.36.9.0036.
  3. ^ Baldessarini RJ, Campbell A, Webb NL, Swindell CS, Flood JG, Shashoua VE, et al. (January 2001). "Fatty acid derivatives of clozapine: prolonged antidopaminergic activity of docosahexaenoylclozapine in the rat". Neuropsychopharmacology. 24 (1): 55–65. doi:10.1016/S0893-133X(00)00173-1. PMID 11106876.